These results suggest that OVs loaded with anti-PD-1 and alendronate activate the anti-tumor immune response in vivo, and play a better role in inhibiting the growth of glioma and prolonging the survival time of tumor-bearing mice. This evidence concerns the gene PDCD1 and central nervous system cancer.